Tan Joanne L C, Barmanray Rahul D, Cirone Bianca, Klarica Daniela, Russell Anthony, Spencer Andrew, Wright Tricia
Department of Malignant Haematology, Transplantation and Cellular Therapies, The Alfred Hospital, Victoria, Australia.
Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Victoria, Australia.
Transplant Cell Ther. 2024 Oct;30(10):970-985. doi: 10.1016/j.jtct.2024.07.014. Epub 2024 Jul 23.
Advances in allogeneic hematopoietic stem cell transplantation (alloHSCT) and supportive care over the past decade have reduced transplant and relapse-related mortality, leading to a greater number of long-term survivors. However, transplant-related late effects, such as cardiovascular disease (CVD) and metabolic diseases, are becoming significant concerns for this group. This review aims to address several key questions regarding cardiovascular late effects in alloHSCT recipients, including the long-term incidence of CVD-related events, the prevalence of risk factors, screening and management recommendations, and evidence for screening and prevention strategies. A literature search was conducted in PubMed Central using the National Library of Medicine search engine, covering all relevant research from inception to 2023. The initial search identified 751 research records, of which 41 were shortlisted based on specific criteria (≥18 years of age at the time of transplant, allogeneic transplant, and inclusion of more than 30 patients). Our review highlights published evidence confirming the increased CVD risk among alloHSCT recipients. This risk is especially pronounced among individuals who have developed traditional and modifiable risk factors or have been exposed to transplant-specific risk factors. Evidence of the use of traditional cardiac risk factor calculators in the alloHSCT population is limited, in addition, there is emerging evidence that general population calculators potentially underestimate CVD risk given the increased risk of CVD in the allogeneic group as a whole. Studies that develop and validate transplant recipient-specific CVD risk stratification tools appear to be severely lacking and the field's focus needs to be shifted here in the coming years. To improve patient engagement and adherence to CVD risk factor measures, we recommend that a multidisciplinary model involving both specialists and primary care physicians is crucial in ensuring regular follow-up in the community and to potentially improve adherence.
在过去十年中,异基因造血干细胞移植(alloHSCT)及支持性治疗取得了进展,降低了移植相关死亡率和复发相关死亡率,从而使长期存活者数量增多。然而,移植相关的晚期效应,如心血管疾病(CVD)和代谢性疾病,正成为这一群体的重大关切。本综述旨在解决关于alloHSCT受者心血管晚期效应的几个关键问题,包括CVD相关事件的长期发生率、危险因素的患病率、筛查和管理建议,以及筛查和预防策略的证据。使用美国国立医学图书馆搜索引擎在PubMed Central上进行了文献检索,涵盖了从开始到2023年的所有相关研究。初步检索确定了751条研究记录,其中41条根据特定标准(移植时年龄≥18岁、异基因移植、纳入患者超过30例)入围。我们的综述强调了已发表的证据,证实alloHSCT受者的CVD风险增加。这种风险在出现传统且可改变的危险因素或接触过移植特异性危险因素的个体中尤为明显。在alloHSCT人群中使用传统心脏危险因素计算器的证据有限,此外,有新证据表明,鉴于异基因群体整体CVD风险增加,一般人群计算器可能低估CVD风险。开发和验证移植受者特异性CVD风险分层工具的研究似乎严重不足,未来几年该领域的重点需要转移到这里。为了提高患者对CVD危险因素措施的参与度和依从性,我们建议涉及专科医生和初级保健医生的多学科模式对于确保在社区进行定期随访并可能提高依从性至关重要。